AAPL   372.69 (-0.31%)
MSFT   208.25 (-1.16%)
FB   240.86 (+0.24%)
GOOGL   1,489.92 (-0.65%)
AMZN   3,000.12 (-1.86%)
NVDA   394.87 (+0.33%)
CGC   16.50 (-2.60%)
BABA   236.51 (-1.45%)
MU   49.09 (-3.59%)
GE   6.76 (-3.43%)
TSLA   1,389.86 (+1.33%)
AMD   52.93 (-0.88%)
T   30.32 (-0.56%)
ACB   12.42 (+1.97%)
F   6.12 (-1.13%)
GILD   76.42 (-0.44%)
DIS   113.63 (-0.69%)
BAC   23.01 (-2.75%)
NFLX   493.16 (-0.13%)
BA   178.88 (-4.81%)
AAPL   372.69 (-0.31%)
MSFT   208.25 (-1.16%)
FB   240.86 (+0.24%)
GOOGL   1,489.92 (-0.65%)
AMZN   3,000.12 (-1.86%)
NVDA   394.87 (+0.33%)
CGC   16.50 (-2.60%)
BABA   236.51 (-1.45%)
MU   49.09 (-3.59%)
GE   6.76 (-3.43%)
TSLA   1,389.86 (+1.33%)
AMD   52.93 (-0.88%)
T   30.32 (-0.56%)
ACB   12.42 (+1.97%)
F   6.12 (-1.13%)
GILD   76.42 (-0.44%)
DIS   113.63 (-0.69%)
BAC   23.01 (-2.75%)
NFLX   493.16 (-0.13%)
BA   178.88 (-4.81%)
AAPL   372.69 (-0.31%)
MSFT   208.25 (-1.16%)
FB   240.86 (+0.24%)
GOOGL   1,489.92 (-0.65%)
AMZN   3,000.12 (-1.86%)
NVDA   394.87 (+0.33%)
CGC   16.50 (-2.60%)
BABA   236.51 (-1.45%)
MU   49.09 (-3.59%)
GE   6.76 (-3.43%)
TSLA   1,389.86 (+1.33%)
AMD   52.93 (-0.88%)
T   30.32 (-0.56%)
ACB   12.42 (+1.97%)
F   6.12 (-1.13%)
GILD   76.42 (-0.44%)
DIS   113.63 (-0.69%)
BAC   23.01 (-2.75%)
NFLX   493.16 (-0.13%)
BA   178.88 (-4.81%)
AAPL   372.69 (-0.31%)
MSFT   208.25 (-1.16%)
FB   240.86 (+0.24%)
GOOGL   1,489.92 (-0.65%)
AMZN   3,000.12 (-1.86%)
NVDA   394.87 (+0.33%)
CGC   16.50 (-2.60%)
BABA   236.51 (-1.45%)
MU   49.09 (-3.59%)
GE   6.76 (-3.43%)
TSLA   1,389.86 (+1.33%)
AMD   52.93 (-0.88%)
T   30.32 (-0.56%)
ACB   12.42 (+1.97%)
F   6.12 (-1.13%)
GILD   76.42 (-0.44%)
DIS   113.63 (-0.69%)
BAC   23.01 (-2.75%)
NFLX   493.16 (-0.13%)
BA   178.88 (-4.81%)
Log in

LON:SNGSynairgen Share Price, Forecast & News

GBX 39
-2.50 (-6.02 %)
(As of 07/7/2020 04:00 PM ET)
Add
Compare
Today's Range
38.27
Now: GBX 39
41.70
50-Day Range
34
MA: GBX 43.29
56
52-Week Range
5.50
Now: GBX 39
81
Volume972,743 shs
Average Volume78,152 shs
Market Capitalization£58.28 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Synairgen plc discovers and develops drugs for respiratory diseases. It develops inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment or prevention of asthma exacerbations caused by the common cold; IFN-ß that is in Phase-I clinical trial for the treatment or prevention of chronic obstructive pulmonary disease exacerbations caused by the common cold; and LOXL2 inhibitor, which is in Phase I clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Synairgen plc has research collaboration with Pharmaxis Ltd. to develop a LOXL2 inhibitor to the lysyl oxidase type 2 enzyme to treat IPF, a lung disease. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.
Read More
Synairgen logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.40 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-23-80512800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£79,000.00
Cash FlowGBX 2.04 per share
Book ValueGBX 2.10 per share

Profitability

Miscellaneous

Employees12
Market Cap£58.28 million
Next Earnings DateN/A
OptionableNot Optionable

Receive SNG News and Ratings via Email

Sign-up to receive the latest news and ratings for SNG and its competitors with MarketBeat's FREE daily newsletter.

Synairgen (LON:SNG) Frequently Asked Questions

How has Synairgen's stock been impacted by COVID-19 (Coronavirus)?

Synairgen's stock was trading at GBX 21.30 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, SNG shares have increased by 83.1% and is now trading at GBX 39. View which stocks have been most impacted by Coronavirus.

Has Synairgen been receiving favorable news coverage?

Media coverage about SNG stock has been trending negative recently, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Synairgen earned a news impact score of -2.1 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news about Synairgen.

Who are some of Synairgen's key competitors?

What other stocks do shareholders of Synairgen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Synairgen investors own include Yamana Gold (YRI), Eldorado Gold (ELD), Polo Resources (POL), Silvercorp Metals (SVM), First Majestic Silver (AG), Ariana Resources (AAU), Alamos Gold (AGI), Basf (BAS), Big Yellow Group (BYG) and Costain Group (COST).

Who are Synairgen's key executives?

Synairgen's management team includes the following people:
  • Mr. Richard Marsden, CEO, MD & Exec. Director (Age 51)
  • Mr. John Ward, Fin. Director, Company Sec. & Exec. Director (Age 57)
  • Dr. Phillip David Monk, Chairman of Scientific Advisory Board, Chief Scientific Officer & Exec. Director (Age 50)
  • Prof. Donna Davies, Co-Founder & Member of Scientific Advisory Board
  • Prof. Ratko Djukanovic, Co-Founder & Member of Scientific Advisory Board

What is Synairgen's stock symbol?

Synairgen trades on the London Stock Exchange (LON) under the ticker symbol "SNG."

How do I buy shares of Synairgen?

Shares of SNG and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Synairgen's stock price today?

One share of SNG stock can currently be purchased for approximately GBX 39.

How big of a company is Synairgen?

Synairgen has a market capitalization of £58.28 million and generates £79,000.00 in revenue each year. Synairgen employs 12 workers across the globe.

What is Synairgen's official website?

The official website for Synairgen is www.synairgen.com.

How can I contact Synairgen?

Synairgen's mailing address is Southampton General Hosp, Tremona Road, SOUTHAMPTON, SO16 6YD, United Kingdom. The company can be reached via phone at +44-23-80512800.

This page was last updated on 7/7/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.